Drugs for Spastic Paraplegia 35, Autosomal Recessive (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 46)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
rimabotulinumtoxinB |
|
Phase 4 |
|
|
|
2 |
|
Piracetam |
Approved, Investigational |
Phase 3 |
|
7491-74-9 |
|
Synonyms:
|
3 |
|
Tacrolimus |
Approved, Investigational |
Phase 2, Phase 3 |
|
104987-11-3 |
445643 439492 6473866 |
Synonyms:
(-)-FK 506
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone
104987-11-3
109581-93-3 (Hydrate)
15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(23H)-tetrone,
3S-[3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5, 19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c] [1,4] oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN
AC-1182
AC1L1K7H
AC1L97GB
AC1L9IBU
Advagraf
AKOS005145901
Ambap104987-11-3
Ambap5429
Anhydrous tacrolimus
Anhydrous, tacrolimus
BCBcMAP01_000194
Bio-0921
Bio2_000470
Bio2_000950
BRD-K35452788-001-02-1
BSPBio_001279
BSPBio-001279
C01375
C44H69NO10
CCRIS 7124
CHEBI:100924
CHEBI:61049
CHEMBL1200738
CID11158639
CID11556866
CID439492
CID445643
CID5372
CID5472317
CID6426916
CID6436007
CID6473866
CID6536850
CID6610362
CID6912836
CID9832283
CID9853905
CID9918805
CID9940643
CID9963169
Cilag brand OF tacrolimus
CPD000466356
CPD-10016
D08556
DB00864
DivK1c_001040
FK 506
FK5
Fk-506
FK506
FK-506
FR 900506
FR900506
|
FR-900506
FT-0082660
Fujimycin
Fujisawa brand OF tacrolimus
Graceptor
HMS1362O21
HMS1792O21
HMS1990O21
HMS2051C18
HMS2093M19
HMS503O21
IDI1_001040
IDI1_002225
Janssen brand OF tacrolimus
K506
KBio1_001040
KBio2_000619
KBio2_003187
KBio2_005755
KBio3_001097
KBio3_001098
KBioGR_000619
KBioSS_000619
L 679934
L-679934
LCP-Tacro
LMPK04000003
LS-64247
MLS000759471
MLS001424054
Modigraf
MolPort-003-666-518
NCGC00163470-01
NCGC00163470-02
NCGC00163470-03
NCGC00163470-04
NCGC00179232-01
NChemBio.2007.16-comp1
nchembio.2007.23-comp2
NINDS_001040
NSC717865
Prograf
Prograf (TN)
Prograft
Protopic
Protopy
S5003_Selleck
SAM001246677
SMR000466356
Tacarolimus
tacrolimus
Tacrolimus
Tacrolimus (anhydrous)
Tacrolimus (INN)
Tacrolimus (Prograf?)
Tacrolimus anhydrous
tacrolimus hydrate
Tacrolimus, anhydrous
Tsukubaenolide
UNII-Y5L2157C4J
|
|
4 |
|
Pancrelipase |
Approved, Investigational |
Phase 2, Phase 3 |
|
53608-75-6 |
|
Synonyms:
lipase
Pancrealipase
Pancreatic extract pancrelipase
Pancreatic protease
|
Pancreatin
Pancreatinum
Pancrelipase (amylase
protease)
|
|
5 |
|
Neuroprotective Agents |
|
Phase 3 |
|
|
|
6 |
|
Protective Agents |
|
Phase 3 |
|
|
|
7 |
|
Botulinum Toxins |
|
Phase 3 |
|
|
|
8 |
|
abobotulinumtoxinA |
|
Phase 3 |
|
|
|
9 |
|
Botulinum Toxins, Type A |
|
Phase 3 |
|
|
|
10 |
|
Immunosuppressive Agents |
|
Phase 2, Phase 3 |
|
|
|
11 |
|
Immunologic Factors |
|
Phase 2, Phase 3 |
|
|
|
12 |
|
Calcineurin Inhibitors |
|
Phase 2, Phase 3 |
|
|
|
13 |
|
pancreatin |
|
Phase 2, Phase 3 |
|
|
|
14 |
|
Amlodipine |
Approved |
Phase 2 |
|
88150-42-9 |
2162 |
Synonyms:
()-Amlodipine
(RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl)
-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyridine
3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester
3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester
3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
3-Ethyl 5-methylester, (±)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl ( -)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat
3-Ethyl-5-methyl ( -)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (.+/-.)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(O-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid
3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
88150-42-9
88150-47-4 (maleate (1:1))
AC1L1D26
AC1Q32ZS
AC-4535
Almirall brand OF amlodipine besilate
Ambap88150-42-9
Amlocard
amlodipine
Amlodipine
Amlodipine (INN)
Amlodipine [INN:BAN]
AMLODIPINE BASE
Amlodipine Benzenesulfonate
Amlodipine besilate
Amlodipine Besilate
Amlodipine besylate
Amlodipine Besylate
Amlodipine free base
Amlodipine Free Base
Amlodipine maleate
Amlodipine maleate (1:1)
Amlodipine, (+-)-isomer
Amlodipine, (+-)-isomer, maleate (1:1)
Amlodipine, (R)-isomer
Amlodipine, (S)-isomer, maleate (1:1)
Amlodipino
Amlodipino [Spanish]
Amlodipinum
Amlodipinum [Latin]
Amlodis
Amlopres
Amlor
|
Amvaz
AMVAZ
Astudal
BIDD:GT0810
BRD-A22032524-074-02-4
BRD-A22032524-074-03-2
BSPBio_002727
C06825
CHEBI:2668
CHEMBL1491
CID2162
Coroval
CPD000469198
D07450
DB00381
Eczacibasi brand OF amlodipine besilate
HMS2052N03
HMS2089H07
I14-0798
Intervask
Istin
KBio3_001947
KBioGR_001643
Lipinox
Lotrel
LS-131183
Mack brand OF amlodipine besilate
MLS001401409
MolPort-001-792-963
NCGC00165957-01
NCGC00165957-02
NCGC00165957-03
Norvasc
Norvasc (TN)
Pelmec
Pfizer brand OF amlodipine besilate
R,S)-Amlodipine
Racemic amlodipine
Racemic Amlodipine
SAM001246705
SMR000469198
SPBio_000351
Spectrum2_000486
Spectrum3_001004
Spectrum4_001132
Spectrum5_001550
UK-4834011
UNII-1J444QC288
|
|
15 |
|
Histamine |
Approved, Investigational |
Phase 2 |
|
51-45-6 |
774 |
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
5-imidazoleethylamine
5-Imidazoleethylamine
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
|
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Ceplene
Dihydrochloride, histamine
Eramin
Ergamine
Ergotidine
Free histamine
Histamine dihydrochloride
Histamine hydrochloride
HSM
Hydrochloride, histamine
L-Histamin base
L-Histamine
Peremin
Theramine
|
|
16 |
|
Famotidine |
Approved |
Phase 2 |
|
76824-35-6 |
3325 |
Synonyms:
(1-amino-3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
(1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
(1-amino-3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulphamide
(1Z)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide
(1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide
3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide
3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulphonyl)propanimidamide
3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine
3-(2-Guanidinothiazol-4-ylmethylthio)-N1-sulfamoylpropionamide
3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N-sulfamoylpropanimidamide
3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpro
3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
76824-35-6
AC-11713
AC1NWASH
AC1Q50E0
AC1Q50E1
Amfamox
Antodine
apo-Famotidine
Apo-Famotidine
Apogastine
Bestidine
BIDD:GT0759
Bio-0739
Blocacid
BPBio1_000098
Brolin
BSPBio_000088
C8H15N7O2S3
CAS-76824-35-6
Cepal
CHEBI:4975
CHEMBL902
CID5702160
Confobos
CPD000058961
Cronol
Cuantin
DB00927
Dibrit 40
Digervin
Dinul
Dipsin
Dispromil
Dispronil
Duovel
Durater
EU-0100497
Evatin
F 6889
F0530
F6889_SIGMA
Fadin
Fadine
Fadyn
Fagastine
Famo
Famocid
Famodar
Famodil
Famodin
Famodine
Famogard
Famonit
Famopsin
Famos
Famosan
Famotal
Famotep
Famotidina
Famotidina [Spanish]
famotidine
Famotidine
Famotidine [USAN:BAN:INN:JAN]
Famotidine hydrochloride
FAMOTIDINE PRESERVATIVE FREE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER
Famotidinum
Famotidinum [Latin]
Famotin
Famovane
Famowal
Famox
Famoxal
Famtac
Famulcer
Fanobel
Fanosin
Fanox
Farmotex
Ferotine
Fibonel
Fluxid
Fudone
Ganor
Gaster
Gastridan
Gastridin
Gastrion
Gastro
Gastrodomina
Gastrofam
Gastropen
Gastrosidin
H2 Bloc
Hacip
HMS1568E10
HMS2051A07
HMS2089I12
|
HS-0054
HSDB 3572
Huberdina
InChI=1/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
Ingastri
Invigan
L 643341
L003830
L013386
Lecedil
Logos
Lopac0_000497
Lopac-F-6889
LS-121117
Mensoma
Midefam
MK 208
MK-208
MLS000028583
MLS000758205
MLS001423994
MolPort-002-557-620
MolPort-003-941-395
Mosul
Motiax
Muclox
Mylanta ar
Mylanta AR
N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine
NCGC00015446-01
NCGC00015446-02
NCGC00015446-03
NCGC00015446-06
NCGC00018276-01
NCGC00018276-02
NCGC00093899-01
NCGC00093899-02
NCGC00093899-03
Neocidine
Nevofam
Notidin
novo-Famotidine
Novo-Famotidine
N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide
N-Sulphamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide
Nu-Famotidine
Nulceran
Nulcerin
Panalba
PDSP1_000398
PDSP2_000396
Pepcid
PEPCID
Pepcid AC
Pepcid AC Gelcaps
PEPCID COMPLETE
PEPCID PRESERVATIVE FREE
PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER
Pepcid RPD
Pepcidac
Pepcidin
Pepcidin pepcidine
Pepcidin Rapitab
Pepcidina
Pepcidine
Pepdif
Pepdine
Pepdul
Pepfamin
Peptan
Peptidin
Peptifam
Pepzan
Prestwick_212
Prestwick2_000104
Prestwick3_000104
Propanimidamide, 3-[[[2-[aminoiminomethyl)amino]-4-thiazoyl]methyl]thio]-N-(aminosulfonyl)
Purifam
Quamatel
Quamtel
Renapepsa
Restadin
Rogasti
Rubacina
SAM001247033
Sedanium-R
Sigafam
SMR000058961
STK527689
Supertidine
Tairal
Tamin
Tipodex
TL8005267
Topcid
Ulcatif
Ulceprax
Ulcofam
Ulfagel
Ulfam
Ulfamid
Ulfinol
Ulgarine
Vagostal
Weimok
Whitidin
Yamarin
YM 11170
YM-11170
YM-1170
|
|
17 |
|
Levetiracetam |
Approved |
Phase 2 |
|
102767-28-2 |
441341 |
Synonyms:
(-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
(2S)-2-(2-oxopyrrolidin-1-yl)butanamide
(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
102767-28-2
AC-1479
AC1NR4PY
alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
BIDD:GT0242
C8H14N2O2
CHEMBL1286
CID5284583
CPD000466303
e Keppra
Etiracetam
Etiracetam levo-isomer
Etiracetam, R-isomer
etiracetam, S-isomer
Etiracetam, S-isomer
FT-0082600
HMS2051D07
HMS2089L20
Keppra
Keppra XR
Keppra, Keppra XR),Levetiracetam
L-059
levetiracetam
Levetiracetam
Levetiracetam [INN]
|
Levetiracetame
Levetiracetamum
Levetiracetamum [INN-Latin]
Levetiractam
Leviteracetam
Levitiracetam
LS-137054
MLS000759403
MLS001424069
MolPort-003-848-377
NCGC00186028-01
S1356_Selleck
SAM001246539
SBB070161
SIB-S1
SMR000466303
TL8000131
Torleva
UCB brand OF levetiracetam
Ucb L059
ucb L060
Ucb L060
UCB-22059
UCB-L 059
Ucb-L059
UCB-L059
Ucb-L060
ZINC01547851
|
|
18 |
|
Acetylcholine |
Approved, Investigational |
Phase 2 |
|
51-84-3 |
187 |
Synonyms:
2-(Acetyloxy)-N,N,N-trimethylethanaminium
Acetilcolina cusi
Acetyl choline ion
Acetylcholine bromide
Acetylcholine cation
acetylcholine chloride
Acetylcholine chloride
Acetylcholine fluoride
Acetylcholine hydroxide
Acetylcholine iodide
Acetylcholine L tartrate
Acetylcholine L-tartrate
Acetylcholine perchlorate
Acetylcholine picrate
Acetylcholine picrate (1:1)
Acetylcholine sulfate (1:1)
Acetylcholinium: acetyl-choline
ACh
Alcon brand OF acetylcholine chloride
|
Azetylcholin
Bournonville brand OF acetylcholine chloride
Bromide, acetylcholine
Bromoacetylcholine
Chloroacetylcholine
Choline acetate
Choline acetate (ester)
Choline acetic acid
Ciba vision brand OF acetylcholine chloride
Cusi, acetilcolina
Fluoride, acetylcholine
Hydroxide, acetylcholine
Iodide, acetylcholine
Iolab brand OF acetylcholine chloride
L-Tartrate, acetylcholine
Miochol
O-Acetylcholine
Perchlorate, acetylcholine
|
|
19 |
|
Iron |
Approved, Experimental |
Phase 2 |
|
15438-31-0, 7439-89-6 |
27284 23925 |
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
armco Iron
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
Fe
FE
FE (II) ion
Fe(2+)
Fe(II)
Fe1+
Fe2+
Fe-40
|
fer
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrous ion
ferrous iron
Ferrousal
Ferrovac e
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hematite
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Infed
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron ion(2+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(2+)
Iron(2+) ion
Iron(II) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, ion (Fe2+)
Iron, reduced
Limonite
LOHA
LS-3196
Magnetite
Malleable iron
Metopirone
Metyrapone
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZH2m
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
PZHO
Reduced iron
Remko
Siderol
Suy-b 2
SUY-B 2
Taconite
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Wrought iron
Yieronia
|
|
20 |
|
Deferiprone |
Approved |
Phase 2 |
|
30652-11-0 |
2972 |
Synonyms:
1,2-Dimethyl-3-hydroxypyrid-4-one
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone
Deferiprona
|
Deferiprone
Défériprone
Deferipronum
|
|
21 |
|
Carbon monoxide |
Approved, Investigational |
Phase 1, Phase 2 |
|
630-08-0 |
281 |
Synonyms:
[co]
C#O
Carbon monoxide
carbon(II) oxide
|
Carboneum oxygenisatum
CO
Monoxide, carbon
|
|
22 |
|
Levodopa |
Approved |
Phase 2 |
|
59-92-7 |
6047 |
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(−)-dopa
(-)-Dopa
(2S)-2-amino-3-(3,4-Dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(2S)-2-amino-3-(3,4-Dihydroxyphenyl)propanoic acid
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
23734-74-9
25525-15-9
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
3 Hydroxy L tyrosine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-dihydroxy-L-phenylalanine
3,4-Dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxyphenylalanine (VAN)
3,4-Dihydroxyphenyl-L-alanine
34241-25-3
37830_FLUKA
3-Hydroxy-L-tyrosine
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
b-(3,4-Dihydroxyphenyl)-L-alanine
Bendopa
beta-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
BIDD:GT0158
Bio-0575
Biodopa
bmse000322
BPBio1_000059
Brocadopa
BSPBio_000053
BSPBio_002354
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
Cerepap
CHEBI:15765
CHEMBL1009
CID6047
Cidandopa
component of Sinemet
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
DOPA
Dopaflex
Dopaidan
Dopal
Dopal-fher
Dopal-Fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
Eldopal
Eldopar
Eldopatec
EU-0100454
Eurodopa
Helfo DOPA
|
helfo-Dopa
Helfo-Dopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
IDI1_000452
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
IV Levodopa
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L 3,4 Dihydroxyphenylalanine
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
l)-L-alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-(3,4-Dihydroxyphenyl)-alanine
L-3,4-dihydroxyphenylalanine
L-3,4-Dihydroxyphenylalanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
Laradopa
Larodopa
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-b-(3,4-Dihydroxyphenyl)alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
L-O-Dihydroxyphenylalanine
L-o-Hydroxytyrosine
Lopac0_000454
Lopac-D-9628
LS-255
L-β-(3,4-dihydroxyphenyl)alanine
Maipedopa
medphano Brand OF levodopa
MLS000028514
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
nchembio.2007.55-comp26
nchembio.89-comp9
ne
NINDS_000452
NSC 118381
NSC118381
Parda
Pardopa
PDSP1_001541
PDSP2_001525
Prestwick_185
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prodopa
Ro 4-6316
Roberts brand OF levodopa
Roche brand OF levodopa
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
Sobiodopa
SPBio_000391
SPBio_001974
Spectrum_000454
Spectrum2_000496
SPECTRUM2300205
Spectrum4_000539
Spectrum5_001899
Syndopa
UNII-46627O600J
Veldopa
Weldopa
β-(3,4-dihydroxyphenyl)alanine
β-(3,4-dihydroxyphenyl)-L-alanine
|
|
23 |
|
Topiramate |
Approved |
Phase 2 |
|
97240-79-4 |
5284627 |
Synonyms:
.beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI)
[(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate
2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulfamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulphamate
2,3:4,5-Bis-O-(1-methylethylidene)-b-D-fructopyranose sulphamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulphamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulphamic acid
2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamic acid
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulphamate
2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulphamic acid
2,3:4,5-Di- O -isopropylidene-(beta)-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulfamic acid
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulphamate
2,3:4,5-Di-O-isopropylidene-b-D-fructopyranose sulphamic acid
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamic acid
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulphamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulphamic acid
2,3:4,5-di-O-isopropylidene-β-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamic acid
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulphamate
2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulphamic acid
2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3-4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, .beta.
97240-79-4
AKOS000424547
beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate
beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate
BIDD:GT0854
BIDD:PXR0127
BRN 5988957
BSPBio_002306
C052342
C07502
C12H21NO8S
CBChromo1_000352
CHEBI:129573
CHEMBL220492
CID5284627
Cilag brand of topiramate
CPD000466325
D00537
DB00273
-D-fructopyranose deriv.
Epitoma
Epitomax
HMS1922H06
HMS2051L09
HMS2093D20
|
HSDB 7531
Janssen brand of topiramate
KS-1122
KW-6485
LS-187392
LS-69764
McN 4853
McN-4853
MCN-4853
MLS000759431
MLS001424070
MolPort-001-615-062
MolPort-002-885-869
NCGC00178714-01
Ortho brand of topiramate
RWJ 17021
RWJ-17021
RWJ-17021-000
S1438_Selleck
SAM001246601
SMR000466325
SPBio_000995
SPECTRUM1505801
Spectrum2_001128
STOCK1N-71037
T0575_SIGMA
Tipiramate
Tipiramate [French]
Tipiramato
Tipiramato [Spanish]
Tipiramic acid
TL8006021
Topamac
Topamax
Topamax (TN)
Topamax sprinkle
Topamax Sprinkle
Topamax, Topiramate
Topimax
Topina
topiramate
Topiramate
Topiramate (JAN/USAN/INN)
Topiramate (TPM)
Topiramate / Placebo
Topiramate [USAN:BAN:INN]
topiramate tablet
Topiramato
Topiramato [INN-Spanish]
Topiramatum
Topiramatum [INN-Latin]
topiramatum [Latin]
Topiramic acid
Topomax
TOR
TPM
UNII-0H73WJJ391
USL-255
|
|
24 |
|
Hormones |
|
Phase 2 |
|
|
|
25 |
|
Calcium, Dietary |
|
Phase 2 |
|
|
|
26 |
|
calcium channel blockers |
|
Phase 2 |
|
|
|
27 |
|
Antihypertensive Agents |
|
Phase 2 |
|
|
|
28 |
|
Vasodilator Agents |
|
Phase 2 |
|
|
|
29 |
|
Antacids |
|
Phase 2 |
|
|
|
30 |
|
Anti-Ulcer Agents |
|
Phase 2 |
|
|
|
31 |
|
Histamine Antagonists |
|
Phase 2 |
|
|
|
32 |
|
Histamine Phosphate |
|
Phase 2 |
|
51-74-1 |
65513 |
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
|
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ
|
|
33 |
|
Histamine H2 Antagonists |
|
Phase 2 |
|
|
|
34 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
35 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
36 |
|
Cholinergic Agents |
|
Phase 2 |
|
|
|
37 |
|
incobotulinumtoxinA |
|
Phase 2 |
|
|
|
38 |
|
Pharmaceutical Solutions |
|
Phase 2 |
|
|
|
39 |
|
Chelating Agents |
|
Phase 2 |
|
|
|
40 |
|
Iron Chelating Agents |
|
Phase 2 |
|
|
|
41 |
|
Anticonvulsants |
|
Phase 2 |
|
|
|
42 |
|
Hypoglycemic Agents |
|
Phase 2 |
|
|
|
43 |
|
Calcium |
Nutraceutical |
Phase 2 |
|
7440-70-2 |
271 |
Synonyms:
Blood coagulation factor XIII
Ca
Ca(2+)
Ca2+
Calcio
Calcium
Calcium element
CALCIUM ion
Calcium, doubly charged positive ion
Calcium, elemental
Coagulation factor XIII
Elemental calcium
Factor XIII
|
Factor XIII a chain
Factor XIII a-chain
Factor XIII transamidase
Factor XIII, coagulation
Fibrin stabilizing factor
Fibrinase
Kalzium
Laki lorand factor
Laki-lorand factor
Stabilizing factor, fibrin
Transamidase, factor XIII
XIII, coagulation factor
|
|
44 |
|
Baclofen |
Approved |
|
|
1134-47-0 |
2284 |
Synonyms:
( inverted question mark)-Baclofen
(?)-Baclofen
(+-)-Baclofen
(+/-)- beta-(Aminoethyl)-4- chlorobenzenepropanoic acid
(+/-)-BACLOFEN
(+/-)-beta-(Aminomethyl)-4-chlorobenzenepropanoic acid
1134-47-0
4-Amino-3-(4-chlorophenyl)butanoic acid
4-amino-3-(4-Chlorophenyl)butyrate
4-amino-3-(4-Chlorophenyl)butyric acid
4-Amino-3-(4-chlorophenyl)butyric acid
62594-36-9
AB00051921
AC1L1DC6
AC-4530
Alphapharm brand OF baclofen
Alphapharm Brand of Baclofen
apo Baclofen
Apo Baclofen
apo-Baclofen
ApoBaclofen
Apo-Baclofen
Apotex brand OF baclofen
Apotex Brand of Baclofen
Ashbourne brand OF baclofen
Ashbourne Brand of Baclofen
ASTA medica brand OF baclofen
ASTA Medica Brand of Baclofen
Athena brand OF baclofen
Athena Brand of Baclofen
Atrofen
AWD, baclofen
AWD, Baclofen
B 5399
b-(4-Chlorophenyl)gaba
b-(Aminomethyl)-4-chlorobenzenepropanoate
b-(Aminomethyl)-4-chlorobenzenepropanoic acid
b-(Aminomethyl)-P-chlorohydrocinnamate
b-(Aminomethyl)-P-chlorohydrocinnamic acid
b-(P-Chlorophenyl)-g-aminobutyrate
b-(P-Chlorophenyl)-g-aminobutyric acid
B3343
B5399_SIGMA
Ba 34647
Ba34,647
Ba-34,647
Ba34647
Ba-34647
baclofen
Baclofen
Baclofen (JP15/USP/INN)
Baclofen (R,S)
Baclofen [USAN:INN:BAN:JAN]
Baclofen alphapharm brand
Baclofen Alphapharm Brand
Baclofen apotex brand
Baclofen Apotex Brand
Baclofen ashbourne brand
Baclofen Ashbourne Brand
Baclofen athena brand
Baclofen Athena Brand
Baclofen awd
Baclofen AWD
Baclofen ciba-geigy brand
Baclofen Ciba-Geigy Brand
Baclofen irex brand
Baclofen Irex Brand
Baclofen isis brand
Baclofen Isis Brand
Baclofen medtronic brand
Baclofen Medtronic Brand
Baclofen novartis brand
Baclofen Novartis Brand
Baclofen nu-pharm brand
Baclofen Nu-Pharm Brand
Baclofen pharmascience brand
Baclofen Pharmascience Brand
Baclofene
Baclofène
Baclofene [INN-French]
Baclofene Irex
Baclofène irex
BaclofeneIrex
Baclofene-Irex
Baclofène-irex
BaclofèneIrex
Baclofeno
Baclofeno [INN-Spanish]
Baclofenum
Baclofenum [INN-Latin]
Baclon
Baclophen
Baclospas
Benzenepropanoic acid, beta-(aminomethyl)-4-chloro-(9CI)
beta-(4-Chlorophenyl)gaba
beta-(Aminomethyl)-4-chlorobenzenepropanoate
beta-(Aminomethyl)-4-chlorobenzenepropanoic acid
beta-(Aminomethyl)-P-chlorohydrocinnamate
beta-(Aminomethyl)-p-chlorohydrocinnamic acid
beta-(Aminomethyl)-P-chlorohydrocinnamic acid
beta-(P-Chlorophenyl)-gamma-aminobutyrate
beta-(p-Chlorophenyl)-gamma-aminobutyric acid
beta-(P-Chlorophenyl)-gamma-aminobutyric acid
Biomol-NT_000251
BPBio1_000012
BPBio1_000750
BRD-A84174873-001-05-2
BRN 2104494
BSPBio_000010
BSPBio_001880
C 34647Ba
C10H12ClNO2
CCRIS 3722
CHEBI:2972
CHEMBL701
Chlorophenyl gaba
Chlorophenyl GABA
Ciba 34,647-Ba
Ciba geigy brand OF baclofen
Ciba Geigy Brand of Baclofen
CIBA34,647ba
|
CIBA-34,647-ba
CIBA34,647BA
CIBA-34,647-BA
Ciba-geigy brand OF baclofen
Ciba-Geigy Brand of Baclofen
CID2284
Clofen
D001418
D00241
DB00181
DivK1c_000001
DL-4-amino-3-P-Chlorophenylbutanoate
DL-4-amino-3-P-Chlorophenylbutanoic acid
DL-4-Amino-3-p-chlorophenylbutanoic acid
DL-Baclofen
EINECS 214-486-9
EU-0100163
GABA, chlorophenyl
GABA, Chlorophenyl
Gabalon
g-amino-b-(P-Chlorophenyl)butyrate
g-amino-b-(P-Chlorophenyl)butyric acid
gamma-amino-beta-(P-Chlorophenyl)butyrate
gamma-amino-beta-(P-Chlorophenyl)butyric acid
gamma-Amino-beta-(p-chlorophenyl)butyric acid
Gen baclofen
Gen Baclofen
Gen-baclofen
GenBaclofen
Gen-Baclofen
Genpharm
HMS1568A12
HMS1920E21
HMS2091M03
HMS500A03
I01-1934
IDI1_000001
Irex brand OF baclofen
Irex Brand of Baclofen
Isis brand OF baclofen
Isis Brand of Baclofen
KBio1_000001
KBio2_000466
KBio2_003034
KBio2_005602
KBio3_001380
KBioGR_000650
KBioSS_000466
Kemstro
Kemstro (TN)
L000002
Lebic
Lioresal
Liorésal
Lioresal (TN)
Lioresal Intrathecal
Lopac0_000163
LS-77134
Medtronic brand OF baclofen
Medtronic Brand of Baclofen
MLS000028480
MolPort-002-051-370
NCGC00015156-05
NCGC00015156-12
NCGC00023843-03
NCGC00024579-03
NCGC00024579-04
NCGC00024579-05
NCGC00024579-06
NINDS_000001
Novartis brand OF baclofen
Novartis Brand of Baclofen
NSC329137
Nu baclo
Nu Baclo
Nu pharm brand OF baclofen
Nu Pharm Brand of Baclofen
Nu-baclo
NuBaclo
Nu-Baclo
Nu-Baclofen
Nu-pharm brand OF baclofen
Nu-Pharm Brand of Baclofen
Oprea1_440627
PCP-GABA
Pharmascience brand OF baclofen
Pharmascience Brand of Baclofen
PMS Baclofen
Pms-Baclofen
PMSBaclofen
PMS-Baclofen
Prestwick_85
Prestwick0_000085
Prestwick1_000085
Prestwick2_000085
Prestwick3_000085
SMP1_000036
SMR000058294
SPBio_000044
SPBio_001949
Spectrum_000066
SPECTRUM1500135
Spectrum2_000092
Spectrum3_000310
Spectrum4_000245
Spectrum5_000852
STK535284
STOCK2S-30552
UNII-H789N3FKE8
UPCMLD-DP142
UPCMLD-DP142:001
β-(4-chlorophenyl)gaba
β-(aminomethyl)-4-chlorobenzenepropanoate
β-(aminomethyl)-4-chlorobenzenepropanoic acid
β-(aminomethyl)-P-chlorohydrocinnamate
β-(aminomethyl)-P-chlorohydrocinnamic acid
β-(P-chlorophenyl)-γ-aminobutyrate
β-(P-chlorophenyl)-γ-aminobutyric acid
γ-amino-β-(P-chlorophenyl)butyrate
γ-amino-β-(P-chlorophenyl)butyric acid
|
|
45 |
|
Zonisamide |
Approved, Investigational |
|
|
68291-97-4 |
5734 |
Synonyms:
1-(1,2-benzisoxazol-3-yl)methanesulfonamide
1-(1,2-Benzoxazol-3-Yl)methanesulfonamide
1,2-Benzisoxazole-3-methanesulfonamide
1,2-Benzisoxazole-3-methanesulphonamide
1,2-benzoxazol-3-ylmethanesulfonamide
3-(Sulfamoylmethyl)-1,2-benzisoxazole
3-(Sulphamoylmethyl)-1,2-benzisoxazole
3-sulfamoylmethyl-1,2-benzisoxazole
3-Sulfamoylmethyl-1,2-benzisoxazole
68291-97-4
AC-1413
AC1L1L0Q
AC1Q55GQ
AD 810
AD-810
AD-810N
AKOS001312269
benzo[D]Isoxazol-3-yl-methanesulfonamide
Benzo[d]isoxazol-3-yl-methanesulfonamide
benzo[D]Isoxazol-3-yl-methanesulphonamide
BIDD:GT0708
BIDD:PXR0183
Bio-0532
BRD-K48300629-001-03-8
BRN 1077076
C022189
C07504
C8H8N2O3S
CHEBI:10127
CHEMBL750
CI 912
CI-912
CID5734
CPD000596519
D00538
DB00909
E-2090
Elan brand of zonisamide
Elan brand OF zonisamide
|
Exceglan
Excegram
Excegran
Excegran (TN)
FT-0082702
HMS2089O07
HSDB 7293
I06-0495
LS-33637
MLS001195632
MLS001306491
MolPort-002-507-855
NCGC00159319-02
NCGC00159319-03
PD 110843
PD-110843
S1445_Selleck
SAM002548957
SMR000596519
SPR_2
STK711131
Tremode
Trerief
UNII-459384H98V
ZINC00004321
Zonegran
Zonegran, Zonisamide
Zonisamida
Zonisamida [Spanish]
zonisamide
Zonisamide
Zonisamide (JAN/USAN/INN)
Zonisamide (ZNS)
Zonisamide [USAN:BAN:INN:JAN]
zonisamide monosodium
Zonisamide monosodium
Zonisamidum
Zonisamidum [Latin]
|
|
46 |
|
GABA Agonists |
|
|
|
|
|
Interventional clinical trials:
(show all 42)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
An Open Label Evaluation of MIDI to Quantify Performance Change in Subjects With Musician's Dystonia After Treatment With Botulinum Toxin Type B (Myobloc ®). |
Completed |
NCT00208091 |
Phase 4 |
Botulinum toxin, type B |
2 |
Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study |
Completed |
NCT00190008 |
Phase 3 |
piracetam |
3 |
Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor by a Multi-center, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study |
Recruiting |
NCT02555982 |
Phase 3 |
BOTOX ® 200 Unités;Placebo |
4 |
Conversion From Immediate Release Tacrolimus to Envarsus XR® in Simultaneous Pancreas-Kidney Recipients: Assessment of Functional, Safety and Quality of Life Outcomes (CIRTEN SPK) |
Suspended |
NCT03769298 |
Phase 2, Phase 3 |
Envarsus XR |
5 |
Trial of Amlodipine Combined With Botulinum Toxin Injections for Focal Dystonia |
Completed |
NCT00015457 |
Phase 2 |
Amlodipine plus Botulinum toxin |
6 |
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Safety, Tolerability and Proof of Concept Study of ST101 for Essential Tremor |
Completed |
NCT01332695 |
Phase 2 |
ST101;Placebo |
7 |
An 'N-of-1' Study of the Histamine H@ Antagonist, Famotidine in Levodopa-induced Dyskinesia in Parkinson's Disease |
Completed |
NCT01937078 |
Phase 2 |
Famotidine |
8 |
A Randomized, Double Blind, Placebo-Controlled, Crossover, Proof of Concept Study to Evaluate the Effectiveness and Safety of Carisbamate in the Treatment of Essential Tremor |
Completed |
NCT00524056 |
Phase 2 |
Carisbamate;Placebo |
9 |
Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia: A Randomized, Double-Blind Placebo-Controlled Cross-Over Study |
Completed |
NCT02199509 |
Phase 2 |
Levetiracetam |
10 |
Deep Brain Stimulation of the Globus Pallidus Interna or the Subthalamic Nucleus for Treatment of Generalized Primary Dystonia |
Completed |
NCT00105430 |
Phase 2 |
|
11 |
Motor Training as Treatment of Focal Hand Dystonia |
Completed |
NCT00021853 |
Phase 2 |
|
12 |
“DOES MYOBLOC™ IMPROVE FUNCTIONAL HAND USE IN YOUNG CHILDREN WITH A HYPERTONIC UPPER EXTREMITY?” |
Completed |
NCT00238641 |
Phase 1, Phase 2 |
Botulinum Toxin type B |
13 |
Deep Brain Stimulation Surgery for Treatment of Focal Hand Dystonia |
Recruiting |
NCT02911103 |
Phase 1, Phase 2 |
|
14 |
Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease |
Active, not recruiting |
NCT02427646 |
Phase 2 |
BoNT-A |
15 |
Ferrochelating Treatment in Patients Affected by "Neurodegeneration With Brain Iron Accumulation" (NBIA) |
Active, not recruiting |
NCT00907283 |
Phase 2 |
Deferiprone |
16 |
Hyperbaric Oxygen for Carbon Monoxide Induced Chronic Encephalopathy |
Not yet recruiting |
NCT04118491 |
Phase 1, Phase 2 |
|
17 |
Anti-Dyskinetic Properties of Topiramate: A Double-Blind, Placebo-Controlled Trial in Patients With Parkinson's Disease and Levodopa-Induced Dyskinesias |
Terminated |
NCT00296959 |
Phase 2 |
topiramate (drug) |
18 |
The Study of Rest Tremor Suppression by Using Electrical Muscle Stimulation |
Unknown status |
NCT02370108 |
Phase 1 |
|
19 |
A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease |
Active, not recruiting |
NCT01621581 |
Phase 1 |
|
20 |
Subthalamic Deep Brain Stimulation in Patients With Medication-Refractory Primary Cranial-Cervical Dystonia: A Randomised, Sham-controlled Trial |
Unknown status |
NCT02583074 |
|
|
21 |
Subthalamic Nucleus (STN) and Globus Pallidus Internus (GPi) Deep Brain Stimulation (DBS) in Patients With Primary Dystonia(RELAX Study) |
Unknown status |
NCT03017586 |
|
|
22 |
Survey of Sensory and Motor Tricks in Focal Dystonia |
Completed |
NCT00054652 |
|
|
23 |
Comparative Study Between the Functional Outcomes of Neuromodulation and Neuroablation Techniques for Treatment of Secondary Dystonia |
Completed |
NCT03347240 |
|
|
24 |
Sensory Training for Treatment of Focal Dystonia |
Completed |
NCT00006336 |
|
|
25 |
Assessing Clinical Effectiveness of Cerebellar Repetitive Transcranial Magnetic Stimulation (rTMS) on Severity of Motor Signs of Essential Tremor |
Completed |
NCT02704793 |
|
|
26 |
Novel Stimulation Patterns and Personalized Deep Brain Stimulation for the Treatment of Dystonia |
Completed |
NCT02468843 |
|
|
27 |
Functional Connectivity of the Basal Ganglia in Primary Focal Dystonia |
Completed |
NCT01761903 |
|
|
28 |
Treatment for Psychogenic Movement Disorders |
Completed |
NCT00314444 |
|
|
29 |
Physical Training Induced Plasticity of Motor Control Mechanisms in Parkinson's Disease Patients |
Completed |
NCT03753503 |
|
|
30 |
Exercise Training in Dystonia and Other Involuntary Movement Disorders |
Recruiting |
NCT03318120 |
|
|
31 |
Probabilistic Determination of the Ventro-intermediate Nucleus of the Thalamus (VIM) Coordinates From Radio-anatomical Landmarks on 1.5 Tesla MRI |
Recruiting |
NCT03696420 |
|
|
32 |
Optimization of VIM Targeting in Essential Tremor Surgery |
Recruiting |
NCT03760406 |
|
|
33 |
Dystonia Genotype-Phenotype Correlation: A Study to Identify Additional Genetic Associations That Contribute to Specific Dystonic Phenotypes |
Recruiting |
NCT03428009 |
|
|
34 |
Deep Brain Stimulation Surgery for Movement Disorders |
Recruiting |
NCT01581580 |
|
|
35 |
Deep Brain Stimulation Therapy in Movement Disorders |
Recruiting |
NCT02119611 |
|
|
36 |
RAD 1601: Pilot Trial of Frameless Virtual Cone Stereotactic Radiosurgical Thalamotomy for Intractable Tremor and Advanced Functional Connectivity Parcellation of the Thalamus |
Recruiting |
NCT03305588 |
|
|
37 |
Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot Study |
Recruiting |
NCT02585583 |
|
|
38 |
Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology |
Enrolling by invitation |
NCT03409120 |
|
|
39 |
Deep Brain Stimulation in Disabling Action Tremor: A Randomized, Double-blind Study Comparing the Ventral Intermediate Nucleus (VIM) of the Thalamus and the Posterior Subthalamic Area (PSA) / Zona Incerta (The TREMORSTIM Study) |
Enrolling by invitation |
NCT03156517 |
|
|
40 |
Studying the Role of the Basal Ganglia in Motor Symptoms Using Deep Brain Stimulation |
Not yet recruiting |
NCT04080674 |
|
|
41 |
Pilot Study of Zonisamide in the Treatment of Essential Tremor |
Terminated |
NCT00616343 |
|
Zonisamide |
42 |
Randomized Controlled Clinical Trial Comparing Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Essential Tremor |
Withdrawn |
NCT02418858 |
|
|
|